Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short-term Investments (2019 - 2025)

Historic Short-term Investments for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $3.0 million.

  • BridgeBio Pharma's Short-term Investments fell 9785.45% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 9785.45%. This contributed to the annual value of $58.9 million for FY2023, which is 5541.52% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Short-term Investments is $3.0 million, which was down 9785.45% from $7.9 million recorded in Q2 2025.
  • BridgeBio Pharma's Short-term Investments' 5-year high stood at $459.2 million during Q2 2021, with a 5-year trough of $177000.0 in Q4 2021.
  • Moreover, its 5-year median value for Short-term Investments was $58.9 million (2023), whereas its average is $144.2 million.
  • Per our database at Business Quant, BridgeBio Pharma's Short-term Investments surged by 2132937.85% in 2022 and then crashed by 9785.45% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Short-term Investments (Quarter) stood at $177000.0 in 2021, then surged by 21329.38% to $37.9 million in 2022, then skyrocketed by 55.42% to $58.9 million in 2023, then soared by 136.49% to $139.4 million in 2024, then plummeted by 97.85% to $3.0 million in 2025.
  • Its Short-term Investments stands at $3.0 million for Q3 2025, versus $7.9 million for Q2 2025 and $139.4 million for Q3 2024.